Table 2.

Ratio of the dose during the evaluation period to the first dose

Dose Ratio, Median (Interquartile Range)nGroup 1 (Intermediate Conversion Factor)nGroup 2 (Higher Conversion Factor)
All patients121.59 (1.19–2.47)361.00 (0.66–1.52)
Age group
 Patients aged 6–11 yr61.81 (0.76–2.50)111.25 (1.00–1.60)
 Patients aged 12–17 yr61.59 (1.25–2.44)250.98 (0.62–1.48)
Previous ESA treatment
 Darbepoetin alfa61.82 (1.17–2.44)191.00 (0.75–1.57)
 Epoetin alfa/beta61.59 (1.25–2.50)171.00 (0.60–1.25)
  • ESA, erythropoiesis-stimulating agent.